Histone deacetylase inhibitors up-regulate the expression of cell surface MHC class-I molecules in B16/BL6 cells.
Komatsu
Y
Y
Pharmaceuticals & Biotechnology Laboratory, Japan Energy Corporation, Saitama, Japan.
Hayashi
H
H
D000818:Animals; D001410:Bacillus megaterium / Q000737:chemistry*; D002087:Butyrates / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D020148:Butyric Acid; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D045782:Hemiterpenes; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D008546:Melanoma, Experimental / Q000276:immunology; D051379:Mice; D010421:Pentanoic Acids / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D015854:Up-Regulation
D002087:Butyrates; D004791:Enzyme Inhibitors; D045782:Hemiterpenes; D015395:Histocompatibility Antigens Class I; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D010421:Pentanoic Acids; D020148:Butyric Acid; C008216:isovaleric acid; C012589:trichostatin A